Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Chagas disease - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

Chagas disease

MONDO:0001444

Also known as:Chagas' diseaseChagas' disease with digestive system involvementChagas' disease with nervous system involvement

Find Clinical TrialsTrials

Overview

A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.

Treatments2 FDA approved

Clinical Trials7 registered · 2 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include common findings: Edema, Pallor, Skin rash, and Heart muscle disease (cardiomyopathy) and others; and sometimes findings: Congestive heart failure, Aganglionic megacolon, Achalasia, and Abnormal large intestine physiology. 27 total HPO annotations.

Organ System	Phenotype Count	Example Features
Digestive system	6	Enlarged spleen (splenomegaly), Diarrhea, Abdominal pain

Diagnosis

Biomarker and diagnostic research for Chagas disease has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for Chagas disease, including BENZNIDAZOLE (BENZNIDAZOLE, approved 2017) and NIFURTIMOX (LAMPIT, approved 2020). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 20 common features.

Estimated prevalence: 1-9 in 1,000,000 (Rare).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

7 clinical trials registered, 2 recruiting. Interventions under study include drug therapy. Pipeline includes 3 PHASE3, 1 PHASE2, 1 PHASE1. Research is primarily industry-sponsored.

NCT ID	Title	Phase	Sponsor	Status
[NCT04024163](https://clinicaltrials.gov/study/NCT04024163)

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:24 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:3386

GARD

Genetic and Rare Diseases Info Center

GARD:18795

Questions for Your Care Team

→What are the benefits and potential side effects of BENZNIDAZOLE for managing Chagas disease?
→Are any of the 7 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Pyronaridine	Pyronaridine	Collaborations Pharmaceuticals, Inc.	2019	—	Designated
4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide	4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide	Center for Discovery & Innovation in Parasitic Diseases	2017	—	Designated
Allopurinol riboside	Allopurinol riboside	Burroughs Wellcome Company	1985	—	Withdrawn

Research Type	Count	% of Total
Research summaries	65	46%
Disease patterns and progression	23	16%
Laboratory research	20	14%
Other research	9	6%
Testing and diagnosis research	9	6%
New treatment approaches	6	4%
Clinical study results	5	4%
Patient case studies	3	2%

Kisho

Chagas disease

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Adverse Event Profiles

Clinical Trials

Recent Publications

Latest News & Developments

Correction to: Rare Pathogenic Variants in Mitochondrial and Inflammation-Associated Genes May Lead to Inflammatory Cardiomyopathy in Chagas Disease.

Chagas disease in Canadian blood donors: 15 years of selective testing.

Chagas disease

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Adverse Event Profiles

Clinical Trials

Recent Publications

Latest News & Developments

Correction to: Rare Pathogenic Variants in Mitochondrial and Inflammation-Associated Genes May Lead to Inflammatory Cardiomyopathy in Chagas Disease.

Chagas disease in Canadian blood donors: 15 years of selective testing.